-
1Academic Journal
Συγγραφείς: T. V. Beketova, E. N. Aleksandrova, T. M. Novoselova, E. G. Sazhina, E. V. Nikolaeva, A. V. Smirnov, V. N. Sorotskaya, E. V. Zemerova, I. F. Nam, N. M. Nikitina, G. S. Arkhangelskaya, Z. R. Bagautdinova, I. N. Dashkov, S. Yu. Chernykh, O. V. Zhirnova, Yu. A. Lushpaeva, L. V. Masneva, I. P. Afanasieva, A. E. Arseniev, I. V. Kondratenko, I. B. Bashkova, S. I. Glukhova, E. L. Nasonov, Т. В. Бекетова, Е. Н. Александрова, Т. М. Новоселова, Е. Г. Сажина, Е. В. Николаева, А. В. Смирнов, В. Н. Сороцкая, Е. В. Земерова, И. Ф. Нам, Н. М. Никитина, Г. С. Архангельская, З. Р. Багаутдинова, И. Н. Дашков, С. Ю. Черных, О. В. Жирнова, Ю. А. Лушпаева, Л. В. Маснева, И. П. Афанасьева, А. Е. Арсеньев, И. В. Кондратенко, И. Б. Башкова, С. И. Глухова, Е. Л. Насонов
Πηγή: Rheumatology Science and Practice; Vol 52, No 2 (2014); 147-158 ; Научно-практическая ревматология; Vol 52, No 2 (2014); 147-158 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20142
Θεματικοί όροι: Wegener's granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrom), biological anti-B cell therapy, rituximab, гранулематоз с полиангиитом Вегенера, микроскопический полиангиит, эозинофильный гранулематоз с поли- ангиитом Черджа–Строс, биологическая анти-В-клеточная терапия
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/1918/1190; Jones R, Cohen Tervaert J, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20. DOI:10.1056/NEJMoa0909169.; Stone J, Merkel P, Spiera R, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vas- culitis. N Engl J Med. 2010;363(3):221–32. DOI:10.1056/NEJMoa0909905.; Luqmani R, Bacon P, Moots R, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671–8.; Hellmich B, Flossman O, Gross WL, et al. EULAR recommenda- tions for conducting clinical studies and/or clinical trials in sys- temic vasculitis: focus on anti-neutrophil cytoplasm antibody- associated vasculitis. Ann Rheum Dis. 2007;66(5):605–17. DOI: http://dx.doi.org/10.1136/ard.2006.062711Epub 2006 Dec 14.; Leavitt RY, Fauci A, Block D, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101–7. DOI: http://dx.doi.org/10.1002/art.1780330807.; Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. DOI:10.1002/art.37715.; Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–100. DOI: http://dx.doi.org/10.1002/art.1780330806.; Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculi- tides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011 Jan;90(1):19–27. DOI:10.1097/MD.0b013e318205a4c6.; Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–23. DOI: http://dx.doi.org/10.1056/NEJMoa1108735.; Bosch X, Guilabert А, Espinosa G, Mirapeix E. Treatment of anti- neutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA. 2007;298(6):655–69. DOI: http://dx.doi.org/10.1001/jama.298.6.655.; Насонов ЕЛ, редактор. Анти-В-клеточная терапия; в ревматологии: фокус на ритуксимаб. Москва: ИМА-Пресс; 2012. 343 с. [Nasonov EL, editor. Anti-В-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cellular therapy in rheumatology: focus on rituksimab]. Moscow: IMA-Press; 2012. 343 p.]; Specks U, Stone JH; the RAVE-ITN Research Group. Long-term efficacy and safety results of the RAVE trial. Clin Exp Immunol. 2011;164:65.; Jones RB, Walsh M, Jayne DRW, et al. Two-year follow-up results from a randomized trial of RTX versus CyP for ANCA-associated renal vasculitis: RITUXVAS. Clin Exp Immunol. 2011;164:57.; Roll P, Ostermeier E, Haubitz M, et al. Efficacy and safety of rit- uximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol. 2012;39(11):2153–6. DOI:10.3899/jrheum.120482. Epub 2012 Sep 15.; Charles P, Neel A, Tieulie N, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multi- centre retrospective study on 80 patients. Rheumatology (Oxford). 2014 Mar;53(3):532-9. DOI:10.1093/rheumatology/ket381. Epub 2013 Nov 26.; Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60(7):2156–68. DOI: http://dx.doi.org/10.1002/art.24637.; Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): com- parison of efficacy in granulomatous versus vasculitic manifesta- tions. Ann Rheum Dis. 2012;71(3):327–33. DOI: http://dx.doi.org/10.1136/ard.2011.153601.; Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryo- globulinemia secondary to hepatitis C virus infection. Autoimmun Rev. 2011;10(11):714–9. DOI: http://dx.doi.org/10.1016/j.autrev.2011.04.033.; Emery P, Mease PJ, Rubbert-Roth A, et al. Retreatment with rit- uximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheuma- toid arthritis: a retrospective pooled analysis. Rheumatology (Oxford). 2011;50(12):2223–32. DOI:10.1093/rheumatology/ker253. Epub 2011 Sep 16.; Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophilcytoplasmic antibody- associated vasculitis. Arthritis Rheum. 2012;64(11):3760–9. DOI: http://dx.doi.org/10.1002/art.34583.; treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625–32. DOI: http://dx.doi.org/10.1002/art.27555.; Wendt M, Gunnarson I, Bratt J, Bruchfeld A. Rituximab in relaps- ing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol. 2012;41(2):116–9. DOI:10.3109/03009742.2011.620573. Epub 2011 Nov 28.; Pullerits R, Ljevakt M, Vikgren J, Bokarewa M. Off-trial evalua- tion of the B cell targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculi- tis: long-term follow-up from a single centre. Scand J Immunol. 2012;76(4):411–20. DOI:10.1111/j.1365-3083.2012.02747.x.; Tesfa D, Ajeganova S, Hä gglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63(8):2209–14. DOI:10.1002/art.30427.; Besada E, Koldingsnes W, Nossent J. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM. 2012;105(6):545–50. DOI: http://dx.doi.org/10.1093/qjmed/hcs015.; Мухин НА, Новиков ПИ, Моисеев СВ и др. Оценка краткосрочной эффективности и безопасности биологических препаратов при различных ревматических заболеваниях – опыт многопрофильного терапевтического стационара. Научно-практическая ревматология. 2013;51(2):138–44. [Mukhin NA, Novikov PI, Moiseev SV, et al. Evaluation of the short-term efficacy and safety of biological agents in different rheumatic diseases: a multidisciplinary thera- peutic hospital’s experience. Nauchno-prakticheskaya revma- tologiya = Rheumatology Science and Practice. 2013;51(2):138–44. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2013-; Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance ther- 640.; apy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol. 2010;5(8):1394–400. DOI: http://dx.doi.org/10.2215/CJN.08821209.; Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in gran- ulomatosis with polyangiitis: results from a single centre. Rheumatology (Oxford). 2013;52(11):2041–7. DOI: http://dx.doi.org/10.1093/rheumatology/ket257.; Kartin-Seba R, Goldbin J, Keoch KA, et al. Rituximab for emmission, induction and maintenance in ANCA-associated vas- culitis: a single centered 10-year experience in 108 patients. Arthritis Rheum. 2010;62 Suppl 10:680.; Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012;39(1):125–30. DOI: http://dx.doi.org/10.3899/jrheum.110143.; Available from: http://www.nice.org.uk/nicemedia/live/13960/65382/65382.pdf; Gregersen JW, Chaudhry A, Jayne DR. Rituximab for ANCA- associated vasculitis in the setting of severe infection. Scand J Rheumatol. 2013;42(3):207–10. DOI: http://dx.doi.org/10.3109/03009742.2012.739638.; Van Oers MH, van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non- Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–8. DOI:10.1200/JCO.2009.26.5827. Epub 2010 May 3.; Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clini- cal trials. J Rheumatol. 2010;37(3):558–67. DOI:10.3899/jrheum.090856. Epub 2010 Jan 28.; Gottenberg JE, Ravaud P, Bardin T, et al.; AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk fac- tors for severe infections in patients with rheumatoid arthritis; Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006;65(8):1116–7. DOI: http://dx.doi.org/10.1136/ard.2005.047308.; Donvik KK, Omdal R. Churg-Strauss syndrome successfully treat- ed with rituximab. Rheumatol Int. 2010;31(1):89–91. DOI:10.1007/s00296-009-1146-6. Epub 2009 Sep 30.; Saech J, Owczarczyk K, Owczarzyk K, et al. Successful use of rit- uximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis. 2010;69(6):1254–5. DOI:10.1136/ard.2009.109850. Epub 2009 Sep 9.; Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011;26(9):2865–71. DOI:10.1093/ndt/gfq852. Epub 2011 Feb 16.; Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associ- ated with diminished T-cell interleukin-5 production. Rheumatology (Oxford). 2008;47(7):1104–5. DOI:10.1093/rheumatology/ken175. Epub 2008 May 20.; Thiel J, Hä ssler F, Salzer U, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangi- itis (Churg-Strauss syndrome). Arthritis Res Ther. 2013;15(5):R133. DOI:10.1186/ar4313.; Bouldouyre M-A, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis. 2009;68(4):606. DOI:10.1136/ard.2008.093773.; Malm IJ, Mener DJ, Kim J, et al. Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab. Otolaryngol Head Neck Surg. 2014 Jan;150(1):68–72. DOI:10.1177/0194599813509784. Epub 2013 Oct 23.; Knight A, Hallenberg H, Baecklund E. Efficacy and safety of rit- uximab as maintenance therapy for relapsing granulomatosis with polyangiitis – a case series. Clin Rheumatol. 2013 Aug 20. DOI:10.1007/s10067-013-2351-y.
-
2Academic Journal
Συγγραφείς: Бекетова, Татьяна, Александрова, Е., Новоселова, Т., Сажина, Е., Николаева, Е., Сороцкая, В., Земерова, Е., Нам, И., Никитина, Н., Архангельская, Г., Багаутдинова, З., Дашков, И., Черных, С., Жирова, О., Лушпаева, Ю., Маснева, Л., Афанасьева, И., Арсеньев, А., Кондратенко, И., Башкова, И., Глухова, С., Насонов, Е., Смирнов, А.
Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ, АССОЦИИРОВАННЫЙ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ, ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ВЕГЕНЕРА, МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ, ЭОЗИНОФИЛЬНЫЙ ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ЧЕРДЖА-СТРОС, БИОЛОГИЧЕСКАЯ АНТИ-В-КЛЕТОЧНАЯ ТЕРАПИЯ, РИТУКСИМАБ, WEGENER''S GRANULOMATOSIS WITH POLYANGIITIS, EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS SYNDROM)
Περιγραφή αρχείου: text/html
-
3Academic Journal
Πηγή: Научно-практическая ревматология.
Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ, АССОЦИИРОВАННЫЙ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ, ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ВЕГЕНЕРА, МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ, ЭОЗИНОФИЛЬНЫЙ ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ЧЕРДЖА-СТРОС, БИОЛОГИЧЕСКАЯ АНТИ-В-КЛЕТОЧНАЯ ТЕРАПИЯ, РИТУКСИМАБ, WEGENER'S GRANULOMATOSIS WITH POLYANGIITIS, EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS SYNDROM), 3. Good health
Περιγραφή αρχείου: text/html
